Advertisement
UK markets closed

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.38
    +1.48 (+1.81%)
     

  • GOLD FUTURES

    2,338.00
    -8.40 (-0.36%)
     

  • DOW

    38,488.18
    +248.20 (+0.65%)
     

  • Bitcoin GBP

    53,620.23
    +340.55 (+0.64%)
     

  • CMC Crypto 200

    1,435.24
    +20.48 (+1.45%)
     

  • NASDAQ Composite

    15,706.30
    +254.99 (+1.65%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

FDA grants accelerated approval to AstraZeneca's ovary cancer drug

Reuters - UK Focus

Dec 19 (Reuters) - AstraZeneca Plc (NYSE: AZN - news) 's ovarian cancer drug has been granted an accelerated approval by the U.S. health regulator, a day after it was approved by the European Commission.

An advisory panel to the U.S. Food and Drug Administration had voted in June against granting an accelerated approval to the drug, Lynparza, citing inadequate data.

Lynparza aims to treat ovarian cancer in patients with certain hereditary gene mutations. (http://1.usa.gov/1sGvFTe) (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Kirti Pandey)